BRIEF

on Zomedica Corp. (NASDAQ:ZOM)

Zomedica's Assisi Loop® Receives Continued Recognition as Fear Free™ Preferred Product

Stock price chart of Zomedica Corp. (EBR:ZOM) showing fluctuations.

Zomedica Corp., a veterinary health company, has announced that its Assisi Loop® product line continues to hold its designation as a Fear Free Preferred Product. This recognition aligns with Fear Free's mission to reduce fear, anxiety, and stress in pets through targeted pulsed electromagnetic field (tPEMF) technology.

Fear Free, known for its efforts to improve veterinary care by addressing the emotional needs of animals, reaffirmed its support for the Assisi Loop® products. These devices are designed to reduce inflammation, accelerate healing, and alleviate canine separation anxiety, offering non-pharmaceutical therapeutic solutions.

Veterinarians like Chris Pachel, DVM, appreciate the collaboration between Fear Free and Zomedica, noting the importance of visibility and support for products that align with Fear Free's mission. Fear Free's Preferred Product Program provides veterinary professionals with reliable tools to enhance the emotional and physical wellbeing of pets.

Zomedica CEO Larry Heaton emphasized that the company's proprietary technology ensures effective therapeutic solutions that can be applied from home, meeting the increasing demand for non-invasive veterinary care.

The Assisi Loop® products are beneficial for various inflammatory conditions, including post-surgical recovery and osteoarthritis. The Calmer Canine Anxiety Treatment System® specifically helps reduce canine anxiety. For more information, visit Assisi LOOP - Assisi (zomedica.com).

R. H.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Zomedica Corp. news